Business Description
Citius Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US17322U3068
Total Employee Number:
23Description
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.68 | |||||
Equity-to-Asset | 0.46 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -4.21 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 15.3 | |||||
3-Year EPS without NRI Growth Rate | 16.2 | |||||
3-Year FCF Growth Rate | 20.9 | |||||
3-Year Book Growth Rate | -40.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.84 | |||||
9-Day RSI | 50.45 | |||||
14-Day RSI | 48.53 | |||||
3-1 Month Momentum % | -29.02 | |||||
6-1 Month Momentum % | -39.45 | |||||
12-1 Month Momentum % | -73.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.58 | |||||
Quick Ratio | 0.16 | |||||
Cash Ratio | 0.08 | |||||
Days Inventory | 6538.27 | |||||
Days Sales Outstanding | 166.79 | |||||
Days Payable | 3501.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -45.6 | |||||
Shareholder Yield % | -301.9 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 80.08 | |||||
Operating Margin % | -1041.51 | |||||
Net Margin % | -823.4 | |||||
EBITDA Margin % | -927.41 | |||||
FCF Margin % | -563.13 | |||||
OCF Margin % | -563.13 | |||||
ROE % | -69 | |||||
ROA % | -35.37 | |||||
ROIC % | -54.82 | |||||
3-Year ROIIC % | -14.48 | |||||
ROC (Joel Greenblatt) % | -6400.87 | |||||
ROCE % | -65.87 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 0.21 | |||||
PS Ratio | 2.31 | |||||
PB Ratio | 0.22 | |||||
EV-to-EBIT | -0.37 | |||||
EV-to-Forward-EBIT | 1.19 | |||||
EV-to-EBITDA | -0.38 | |||||
EV-to-Revenue | 3.57 | |||||
EV-to-Forward-Revenue | 0.23 | |||||
EV-to-FCF | -0.63 | |||||
Earnings Yield (Greenblatt) % | -270.27 | |||||
FCF Yield % | -194.18 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CTXR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Citius Pharmaceuticals Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5.611 | ||
| EPS (TTM) ($) | -2.571 | ||
| Beta | 0.5833 | ||
| 3-Year Sharpe Ratio | -0.61 | ||
| 3-Year Sortino Ratio | -0.94 | ||
| Volatility % | 65.07 | ||
| 14-Day RSI | 48.53 | ||
| 14-Day ATR ($) | 0.047479 | ||
| 20-Day SMA ($) | 0.565963 | ||
| 12-1 Month Momentum % | -73.4 | ||
| 52-Week Range ($) | 0.476 - 2.19 | ||
| Shares Outstanding (Mil) | 27.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Citius Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Citius Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2026-12-23 | In 168 days | ||
| Fourth quarter earnings results for 2026 | 2026-12-23 | In 168 days | ||
| Third quarter earnings results for 2026 | 2026-08-12 | In 35 days | ||
| Second quarter earnings results for 2026 | 2026-05-15 | 0.72 (+7.48%) | ||
| General meeting for 2025 | 2026-04-06 08:00 | 0.85 (+1.69%) | ||
| First quarter earnings results for 2026 | 2026-02-13 | 0.79 (-15.60%) | ||
| Annual report for 2025 | 2025-12-23 | 1.05 (-2.78%) | ||
| Fourth quarter earnings results for 2025 | 2025-12-23 | 1.05 (-2.78%) | ||
| Think Equity Conference | 2025-10-30 | 1.51 (-2.58%) | ||
| LD Micro Main Event XIX | 2025-10-19 | 1.45 (-0.68%) |
Show
Entries
Citius Pharmaceuticals Inc Frequently Asked Questions
What is Citius Pharmaceuticals Inc(CTXR)'s stock price today?
The current price of CTXR is $0.59. The 52 week high of CTXR is $2.19 and 52 week low is $0.48.
When is next earnings date of Citius Pharmaceuticals Inc(CTXR)?
The next earnings date of Citius Pharmaceuticals Inc(CTXR) is 2026-08-12 Est..
Does Citius Pharmaceuticals Inc(CTXR) pay dividends? If so, how much?
Citius Pharmaceuticals Inc(CTXR) does not pay dividend.
Guru Commentaries on NAS:CTXR
No articles.
Press Release
Articles on Citius Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers